S
46.83
1.78 (3.95%)
| Previous Close | 45.05 |
| Open | 45.09 |
| Volume | 1,710,248 |
| Avg. Volume (3M) | 2,598,234 |
| Market Cap | 4,777,009,152 |
| Price / Sales | 13.14 |
| Price / Book | 19.52 |
| 52 Weeks Range | |
| Earnings Date | 14 Nov 2025 |
| Diluted EPS (TTM) | -2.55 |
| Total Debt/Equity (MRQ) | 20.22% |
| Current Ratio (MRQ) | 10.25 |
| Operating Cash Flow (TTM) | -229.84 M |
| Levered Free Cash Flow (TTM) | -134.32 M |
| Return on Assets (TTM) | -50.15% |
| Return on Equity (TTM) | -106.71% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Scholar Rock Holding Corporatio | Mixed | Bullish |
AIStockmoo Score
-1.3
| Analyst Consensus | -2.5 |
| Insider Activity | -3.0 |
| Price Volatility | -5.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 4.0 |
| Average | -1.30 |
|
Scholar Rock Holding Corp is a late-stage biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for treating serious diseases in which signaling by protein growth factors plays a fundamental role. Its pipeline includes Neuromuscular and Obesity, Immuno-oncology, Fibrotic Disease, and Hematology. The group operates and manages its business as a single segment to assess performance and make operating decisions. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 4.35% |
| % Held by Institutions | 118.63% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 53.00 (B of A Securities, 13.18%) | Buy |
| Median | 45.00 (-3.91%) | |
| Low | 42.00 (Wolfe Research, -10.31%) | Buy |
| Average | 46.57 (-0.56%) | |
| Total | 7 Buy | |
| Avg. Price @ Call | 36.07 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| JP Morgan | 18 Nov 2025 | 47.00 (0.36%) | Buy | 39.81 |
| Wolfe Research | 18 Nov 2025 | 42.00 (-10.31%) | Buy | 39.81 |
| Barclays | 17 Nov 2025 | 45.00 (-3.91%) | Buy | 36.47 |
| 24 Sep 2025 | 44.00 (-6.04%) | Buy | 33.72 | |
| Truist Securities | 20 Oct 2025 | 44.00 (-6.04%) | Buy | 27.92 |
| B of A Securities | 09 Oct 2025 | 53.00 (13.18%) | Buy | 40.99 |
| Piper Sandler | 24 Sep 2025 | 51.00 (8.90%) | Buy | 33.72 |
| HC Wainwright & Co. | 23 Sep 2025 | 44.00 (-6.04%) | Buy | 33.75 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| QATANANI MO | - | 45.20 | -136,462 | -6,168,082 |
| Aggregate Net Quantity | -136,462 | |||
| Aggregate Net Value ($) | -6,168,082 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 45.20 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| QATANANI MO | Officer | 04 Dec 2025 | Automatic sell (-) | 136,462 | 45.20 | 6,168,082 |
| QATANANI MO | Officer | 04 Dec 2025 | Option execute | 136,462 | - | - |
| Date | Type | Details |
|---|---|---|
| 13 Dec 2025 | Announcement | Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 18 Nov 2025 | Announcement | Scholar Rock to Present at Upcoming Investor Conferences |
| 14 Nov 2025 | Announcement | Scholar Rock Reports Third Quarter 2025 Financial Results and Recent Business Highlights |
| 12 Nov 2025 | Announcement | Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 04 Nov 2025 | Announcement | Scholar Rock to Present at the 2025 Jefferies Global Healthcare Conference |
| 23 Oct 2025 | Announcement | Scholar Rock to Report Third Quarter 2025 Financial Results on November 14, 2025 |
| 17 Oct 2025 | Announcement | Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 23 Sep 2025 | Announcement | FDA Issues Complete Response Letter (CRL) for Apitegromab as a Treatment for Patients with Spinal Muscular Atrophy (SMA) Solely Related to Observations Identified at Catalent Indiana LLC Fill-Finish Facility |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |